Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)
-
Published:2018-11
Issue:
Volume:13
Page:123-135
-
ISSN:2212-1374
-
Container-title:Journal of Bone Oncology
-
language:en
-
Short-container-title:Journal of Bone Oncology
Author:
Coleman R.E., Collinson M.ORCID, Gregory W., Marshall H.ORCID, Bell R., Dodwell D., Keane M., Gil M.ORCID, Barrett-Lee P., Ritchie D., Bowman A., Liversedge V., De Boer R.H., Passos-Coelho J.L., O'Reilly S., Bertelli G.ORCID, Joffe J., Brown J.E., Wilson C., Tercero J.C., Jean-Mairet J., Gomis R., Cameron D.
Reference27 articles.
1. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study;Fitzmaurice;JAMA Oncol.,2017 2. Cancer to bone: a fatal attraction;Weilbaecher;Nat. Rev Cancer,2011 3. The influence of the pre-metastatic niche on breast cancer metastasis;Ursini-Siegel;Cancer Lett.,2016 4. Breast cancer adjuvant therapy with zoledronic acid;Coleman;New Engl. J. Med.,2011 5. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomized open-label phase 3 trial;Coleman;Lancet Oncol.,2014
Cited by
75 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|